Published in:
01-03-2014 | Invited Commentary
Surgical treatment for obstructive hypertrophic cardiomyopathy
Authors:
Kenji Minakata, Ryuzo Sakata
Published in:
General Thoracic and Cardiovascular Surgery
|
Issue 3/2014
Login to get access
Excerpt
Hypertrophic cardiomyopathy (HCM) is one of the most common genetic diseases affecting myocardium with wide variety of clinical manifestation, hemodynamic characteristics, anatomic morphology, and natural history. Patients with HCM may develop limiting symptoms due to dynamic left ventricular outflow tract obstruction (LVOTO) and associated mitral regurgitation (MR) due to systolic anterior motion (SAM) of the anterior mitral leaflet [
1]. For those who have severe symptoms unresponsive to maximum medical therapy including beta-blockers and antiarrhythmic drugs such as disopyramide or cibenzoline, surgical left ventricular septal myectomy has been the standard option. It has been shown that septal myectomy significantly decreases LVOT gradient and associated MR and provides excellent long-term outcomes. …